Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease

Summary

This is a phase I, interventional, single arm, open-label, clinical study to evaluate the safety and efficacy of the striatal transplantation of autologous induced neural stem cell-derived DA precursor cells in Parkinson's Disease patients.

Timeline

Start

2021-04-01

Primary completion

2027-12-31

Completion

2028-12-31

Drugs

Indications